Inhaled 3% hypertonic saline shows promise for antibiotic-naïve NTM lung disease
Inhaled 3% hypertonic saline is associated with improved symptoms and microbiological stabilization in patients with antibiotic-naïve NTM-LD.
Asset / Drug
Drug and asset intelligence for Inhaled with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.